1 Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2

- 2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial
- 3 Chijioke Bennett, Novavax, Inc., Gaithersburg, MD, 20878, USA;
- E Joy Rivers, Novavax, Inc., Gaithersburg, MD 20878, USA;* 4
- 5 Wayne Woo, Novavax, Inc., Gaithersburg, MD 20878, USA;
- 6 Mark Bloch, Holdsworth House Medical Practice, Sydney, AU and Kirby Institute, University of
- 7 New South Wales, Sydney, AU;
- 8 King Cheung, Emeritus Research, Camberwell, AU;
- 9 Paul Griffin, Mater Misericordiae Ltd and University of Oueensland, South Brisbane, AU;
- 10 Rahul Mohan, Paratus Clinical Research Western Sydney, Blacktown, AU;
- 11 Sachin Deshmukh, Griffith University, Southport, AU;
- 12 Mark Arya, Australian Clinical Research Network (ACRN), Anzac Parade Maroubra, AU;
- 13 Oscar Cumming, Novatrials, Newcastle, AU;
- 14 A. Munro Neville, AusTrials, Brisbane, AU;
- 15 Toni McCallum Pardey, Novatrials, Newcastle, AU;
- 16 Joyce S Plested, Novavax, Inc., Gaithersburg, MD 20878, USA;
- 17 Shane Cloney-Clark, Novavax, Inc., Gaithersburg, MD 20878, USA;
- Mingzhu Zhu, Novavax, Inc., Gaithersburg, MD 20878, USA; 18
- 19 Raj Kalkeri, Novavax, Inc., Gaithersburg, MD 20878, USA;
- 20 Nita Patel, Novavax, Inc., Gaithersburg, MD 20878, USA;

- 21 Agi Buchanan, Novavax, Inc., Gaithersburg, MD 20878, USA;**
- 22 Alex Marcheschi, Novavax, Inc., Gaithersburg, MD 20878, USA;
- 23 Jennifer Swan, Novavax, Inc., Gaithersburg, MD 20878, USA;
- 24 Gale Smith, Novavax, Inc., Gaithersburg, MD 20878, USA;
- 25 Iksung Cho, Novavax, Inc., Gaithersburg, MD 20878, USA;
- 26 Gregory M. Glenn, Novavax, Inc., Gaithersburg, MD 20878, USA;
- 27 Robert Walker, Novavax, Inc., Gaithersburg, MD 20878, USA; and
- 28 Raburn M. Mallory, Novavax, Inc., Gaithersburg, MD 20878, USA; on behalf of the Novavax
- 29 Inc. 2019nCoV-311 Study Group
- 30 ^{*}formerly Novavax and currently at Protara Therapeutics
- 31 ** formerly Novavax and currently HilleVax, Inc., Boston, Massachusetts, United States
- 32

33 Corresponding Author:

- 34 Chijioke Bennett, MD
- 35 Novavax, 21 Firstfield Rd., Gaithersburg, MD, 20878
- 36 <u>CBennett@novavax.com</u>; T: +1 (240) 268-2000
- 37

38 Alternate Corresponding Author:

- 39 Alex Marcheschi
- 40 21 Firstfield Rd., Gaithersburg, MD 20878

- 41 AMarcheschi@Novavax.com
- 42
- 43 Running title: NVX-CoV2373 BA.1/bivalent vaccine
- 44 Keywords: SARS-CoV-2; COVID-19; vaccine; booster; immunogenicity
- 45
- 46 Abstract word count (limit 200): 200
- 47 Manuscript word count (limit 3500): 3500
- 48 Figures/tables (limit 7): 7
- 49 References (limit 50): 22

50

Background. Mutations present in emerging SARS-CoV-2 variants permit evasion of
neutralization with prototype vaccines. A novel Omicron BA.1 subvariant-specific vaccine
(NVX-CoV2515) was tested alone, or as a bivalent preparation in combination with the
prototype vaccine (NVX-CoV2373), to assess antibody responses to SARS-CoV-2.
Methods. Participants aged 18 to 64 years immunized with 3 doses of prototype mRNA vaccines
were randomized 1:1:1 to receive a single dose of NVX-CoV2515, NVX-CoV2373, or bivalent
mixture in a phase 3 study investigating heterologous boosting with SARS-CoV-2 recombinant
spike protein vaccines. Immunogenicity was measured 14 and 28 days after vaccination for the
SARS-CoV-2 Omicron BA.1 sublineage and ancestral strain. Safety profiles of vaccines were
assessed.

- 61 Results. Of participants who received trial vaccine (N=829), those administered NVX-CoV2515
- 62 (n=286) demonstrated superior neutralizing antibody response to BA.1 versus NVX-CoV2373
- (n=274) at Day 14 (geometric mean titer ratio [95% CI]: 1.6 [1.33, 2.03]). Seroresponse rates 63
- [n/N; 95% CI] were 73.4% [91/124; 64.7, 80.9] for NVX-CoV2515 versus 50.9% [59/116; 41.4, 64
- 65 60.3] for NVX-CoV2373. All formulations were similarly well-tolerated.
- Conclusions. NVX-CoV2515 elicited a superior neutralizing antibody response against the 66
- 67 Omicron BA.1 subvariant compared with NVX-CoV2373 when administered as a fourth dose.
- Safety data were consistent with the established safety profile of NVX-CoV2373. 68
- 69

70 Introduction

71 Since the COVID-19 outbreak in late 2019, several variants of SARS-CoV-2 (e.g., Alpha, Beta, 72 Gamma, and Delta) have emerged with mutations in key antigenic sites in the receptor binding 73 domain and spike protein. In late 2021, the Omicron variant emerged as the dominant circulating 74 SARS-CoV-2 virus throughout the world, replacing earlier strains/variants. The emergence and 75 propagation of SARS-CoV-2 variants, such as the Omicron sublineages, has complicated the 76 COVID-19 vaccine landscape. Initial actions to stay ahead of SARS-CoV-2 evolution included 77 directives from the US Food and Drug Administration (FDA) to develop vaccines containing an 78 Omicron component [1,2]. 79 Large phase 3 clinical trials for prototype COVID-19 vaccines were conducted prior to the 80 extensive prevalence of variant strains [3-6]. High vaccine efficacy against the ancestral 81 (Wuhan) strain of SARS-CoV-2 was reported in the phase 3 trial of BNT162b2 82 (Pfizer/BioNTech, July 2020-November 2020) [3], the phase 3 trial of mRNA-1273 (Moderna, 83 July 2020-October 2020) [4], the UK-based phase 3 trial of the Matrix-M-adjuvanted, 84 recombinant spike protein COVID-19 vaccine NVX-CoV2373 [5], and the pivotal US phase 3 85 trial of NVX-CoV2373 [6]. Multiple recent studies have demonstrated that newly emerging Omicron sublineages are less efficiently neutralized than the ancestral SARS-CoV-2 strain by 86 87 approved prototype COVID-19 mRNA vaccines, including the BNT162b2 and mRNA-1273 88 vaccines [7-9]. As of June 2022, regulatory bodies have instructed COVID-19 vaccine 89 manufacturers to develop bivalent vaccines consisting of the ancestral and Omicron BA.4/BA.5 90 subvariant strains to potentially provide increased protection from COVID-19 infection [1]; 91 notably, a number of manufacturers already had bivalent vaccines consisting of the ancestral and 92 Omicron BA.1 subvariant strains in development. Currently, the US FDA has granted emergency

93	use authorization of two mRNA-based bivalent vaccines targeting the Omicron sublineage
94	[10,11]; however, sparse real-world data exist about the comparative effectiveness of
95	monovalent versus bivalent SARS-CoV-2 vaccines. In June 2023 during a Vaccines and Related
96	Biological Products Advisory Committee (VRBPAC) Meeting, the FDA recommended
97	development of a monovalent Omicron XBB-sublineage vaccine for the 2023-2024 vaccination
98	campaign [12]. The World Health Organization (WHO) Technical Advisory Group on COVID-
99	19 Vaccine Composition (TAG-CO-VAC), as well as the European Center for Disease
100	Prevention and Control (ECDC) and European Medicines Agency (EMA) have made similar
101	recommendations about updating vaccines to target XBB strains [13,14].
102	As part of the evaluation of Omicron-targeted vaccines, Novavax produced a novel Omicron
103	BA.1 subvariant-specific vaccine (NVX-CoV2515) based on the same recombinant spike protein
104	technology as its authorized prototype vaccine, NVX-CoV2373. Similarly, NVX-CoV2515 is
105	also a co-formulated product consisting of full-length, pre-fusion recombinant S protein trimers
106	with the saponin-based adjuvant, Matrix-M [™] . NVX-CoV2515 was prepared for use either alone
107	or in combination with the prototype vaccine (NVX-CoV2373) as a bivalent mixture to
108	determine whether it would enhance or broaden antibody responses across variants of concern.
109	To provide real-world applicable data, the population planned for investigation included
110	participants who had already received 3 prior vaccinations with mRNA-based vaccines produced
111	by Moderna and Pfizer BioNTech (i.e., mRNA-1273 and BNT162b2, respectively).
112	Here, we describe interim results from an ongoing, phase 3, randomized, observer-blinded
113	clinical trial (NCT05372588) evaluating the immunogenicity and safety of an Omicron BA.1-
114	containing monovalent vaccine (NVX-CoV2515) and a bivalent vaccine (NVX-CoV2373 +
115	NVX-Cov2515) compared with the original NVX-CoV2373 booster. The goal of this interim

analysis was to determine if NVX-CoV2515 induces superior antibody responses to the Omicron

117 BA.1 subvariant compared with the antibody response induced by NVX-CoV2373.

118 Methods

- 119 As part of an ongoing phase 3, randomized, observer-blinded study (NCT05372588), participants
- 120 who previously received a regimen of 3 doses of mRNA-1273 and/or BNT162b2 were
- 121 randomized 1:1:1 to receive NVX-CoV2373, NVX-CoV2515, or bivalent mixture as a
- 122 heterologous fourth dose. Eligible participants were ≥ 18 and ≤ 64 years of age and received their
- 123 last dose of mRNA vaccine \geq 90 days prior to their planned study vaccination. Baseline
- 124 SARS-CoV-2 positivity by either polymerase chain reaction (PCR) or anti-nucleocapsid (anti-N)
- 125 diagnostics was confirmed.
- 126 Participants received randomized investigational vaccines containing 5 µg SARS-CoV-2
- 127 recombinant Spike (rS) protein and 50 µg Matrix-M adjuvant administered via a 0.5 mL
- 128 intramuscular injection. The bivalent vaccine was prepared on-site as a 1:1 mixture of NVX-
- 129 CoV2373 and NVX-CoV2515. Following vaccination, participants utilized an electronic diary to
- 130 record daily solicited local and systemic reactions for 7 days. Unsolicited adverse events (AEs)
- 131 were collected for 28 days following vaccination. Data were analyzed from three participant
- 132 analysis sets: the Safety Analysis Set included all participants who provided consent, were
- 133 randomized, and received the study vaccine; the Per-Protocol Analysis Set 1 (PP1) population
- 134 included participants who received the study vaccine, had serology results for baseline and an
- analyzed time point, were negative at baseline for SARS-CoV-2, and had no major protocol
- 136 violations or event (e.g., COVID-19 infection) that could potentially impact immune responses;
- 137 the Per-Protocol Analysis Set 2 (PP2) population was defined exactly as the PP1 population

138 excluding the requirement for participants to have a negative baseline anti-N result. PP1 and PP2 139 results were determined for each strain/subvariant, serology assay, and study visit. 140 Immune responses were assessed at 14 and 28 days following vaccination. Participant serum 141 collected at each timepoint was analyzed using live-virus neutralization [15], anti-spike 142 immunoglobulin G (IgG) antibody [15], and pseudovirus neutralization assays [16]. Live-virus 143 neutralization assays provided microneutralization with an inhibitory concentration of 50% 144 (MN₅₀) data for the Omicron BA.1 sublineage (Day 14, primary endpoint) and ancestral strain 145 (validated by 360biolabs [Melbourne, Australia]). The 95% CI for geometric mean titer (GMT) 146 and geometric mean fold rise (GMFR) were obtained based on a t-distribution of the log-147 transformed values. The GMT ratio (GMTR) at Day 14 and the two-sided 95% CIs were 148 computed using the analysis of covariance (ANCOVA), with the vaccine group as the fixed 149 effect and the titer at Day 0 as the covariate under a two-sided type I error rate of 0.05. Statistical 150 significance was achieved if the lower-bound of the two-sided 95% CI was above unity (i.e., >1). 151 Seroresponse rates (SRRs) in MN₅₀ titers (defined as a \geq 4-fold increase from baseline values) of 152 the Omicron BA.1 subvariant at Day 14 following study vaccination were analyzed as part of the 153 primary endpoint. Two-sided exact binomial 95% CIs were calculated using the Clopper-Pearson 154 method. The difference in SRR between groups (expressed as NVX-CoV2515 minus NVX-155 CoV2373) was also calculated, with the 95% CI for the difference based on the method of 156 Miettinen and Nurminen. For the analysis of difference of SRRs, assuming 80% SRR for NVX-157 CoV2373 and 85% SRR for NVX-CoV2515, there was 90% power to conclude non-inferiority 158 using a margin of -5% (NVX-CoV2515 relative to NVX-CoV2373). Serum anti-spike IgG 159 enzyme linked immunosorbent assays (ELISAs) measured participant serum antibody 160 concentrations (EU/mL) against the recombinant spike protein of the ancestral strain and

161 Omicron BA.1 sublineage (validated by Novavax Clinical Immunology [Gaithersburg,

162 Maryland, USA]). As an exploratory endpoint, pseudovirus neutralization assays provided 50%

163 inhibitory dilution (ID₅₀) data for the ancestral strain and Omicron BA.1 sublineage (validated by

164 Monogram Biosciences [South San Francisco, CA, USA]).

165 Sample size determination was based on the co-primary endpoints of MN₅₀ GMT and SRR. For

166 the GMTR analysis a standard deviation of 0.6 for log10-transformed neutralization titers based

167 on data from previous studies, a 15% non-evaluable allowance, and an overall one-sided type I

168 error of 2.5% was assumed. Study enrollment was halted ahead of reaching the planned

169 population after re-examination of the sample size approximations suggested that the necessary

170 number of participants had already been achieved to assess the primary endpoints.

171 The trial protocol was approved by the Alfred Hospital Ethics Committee (Melbourne, Victoria,

172 Australia) and the Bellberry Human Research Ethics Committee (Adelaide, South Australia), and

173 is registered on Clinicaltrials.gov (NCT05372588). This study was performed in accordance with

174 the International Conference on Harmonization, Good Clinical Practice guidelines. All

175 participants provided informed consent prior to study participation.

176 Randomization was managed by a contract research organization (CRO), and treatments were

177 assigned using an Interactive Web Response System (IWRS). The block size was blinded

178 information and known only by the CRO statistician. Predetermined site personnel were

179 unblinded to enable vaccine preparation and administration without breaking the blind for other

180 personnel or participants. Only blinded personnel could perform study related assessments or

181 have participant contact for data collection after administration of study vaccine.

182 **Results**

- 183 From 31 May 2022 to 17 July 2022, a total of 835 participants (from 19 study sites across
- 184 Australia) were screened and 831 participants were randomized to one of three treatment groups.
- 185 Of the randomized participants, 829 received vaccine: 286 received NVX-CoV2515, 274
- received NVX-CoV2373, and 269 received bivalent vaccine (Safety Analysis Set) (Supp Figure

187 **1**).

- 188 Demographic and other baseline characteristics of the participants in the Safety Analysis Set
- 189 were similar across all vaccine groups (**Table 1**). The median age was 41.0 to 42.0 years, the
- 190 majority of participants in each group were female (52.2% [NVX-CoV2373, 143/274] to 56.1%
- 191 [bivalent, 151/269]), and most participants were White (≥78.5% [NVX-CoV2515, 233/286;
- 192 NVX-CoV2373, 215/274; bivalent, 220/269]) and of Australian ethnicity (≥86.1% [NVX-
- 193 CoV2515, 252/286; NVX-CoV2373, 236/274; bivalent, 233/269]). Baseline SARS-CoV-2
- 194 exposure was substantial, with \geq 50.9% (NVX-CoV2515, 149/286; NVX-CoV2373, 145/274;
- bivalent, 137/269) of participants testing positive by either PCR or anti-N serology. These
- 196 participants were excluded from the primary endpoint analysis of the Per-Protocol Analysis Set 1
- 197 (PP1), however were included in complementary analyses of the Per-Protocol Analysis Set 2
- 198 (PP2) to provide data more representative of a "real world" population. Demographic and other
- 199 baseline characteristics of participants in the PP1 and PP2 populations were similar to those in
- 200 the Safety Analysis Set and were generally well balanced across the treatment groups (Supp
- 201 **Table 1**).

202 Per Protocol Analysis Set 1:

203	Among participants with no evidence of SARS-CoV-2 exposure at baseline (PP1 population),
204	strong immune responses were observed following administration with all 3 investigational
205	vaccines at 14 days post-vaccination (Table 2). At Day 14, microneutralization assay GMTs
206	against the Omicron BA.1 sublineage were the highest in participants receiving NVX-CoV2515,
207	followed by those receiving the bivalent vaccine and NVX-CoV2373 (MN_{50} titers [95% CI] of
208	130.8 [109.2, 156.7], 97.9 [81.3, 117.9], and 83.9 [69.6, 101.2], respectively) (Figure 1). Formal
209	comparison of NVX-CoV2515 and NVX-CoV2373 resulted in a GMTR of 1.6 (95% CI: 1.33,
210	2.03) indicating a significant difference between the vaccines (Table 2). NVX-CoV2515 induced
211	a non-inferior SRR against the Omicron BA.1 subvariant virus versus NVX-CoV2373 (73.4%
212	[91/124] vs 50.9% [59/116]) at Day 14, with a difference in SRRs of 22.5% (95% CI: 10.3, 34.2)
213	(Table 2). MN ₅₀ GMTs for the ancestral strain microneutralization assay were somewhat lower
214	in participants receiving NVX-CoV2515 compared with the bivalent vaccine and NVX-
215	CoV2373 alone (MN ₅₀ titers [95% CI] of 1076.3 [908.4, 1275.4], 1319.9 [1120.1, 1555.3], and
216	1442.5 [1192.4, 1745.0], respectively) (Figure 1). Similar findings were seen at Day 28.
217	Anti-spike IgG assay data indicate that the highest concentrations of Omicron BA.1 IgG are
218	achieved with NVX-CoV2373, highlighting the vaccine's cross-reactive nature with the Omicron
219	BA.1 sublineage. Anti-spike IgG antibody levels (geometric mean ELISA units, GMEU) [95%
220	CI] for the BA.1 assay were 30,170.9 [25,663.7, 35,469.6], 24,174.8 [20,943.6, 27,904.6], and
221	23,045.5 [20,113.5, 26,404.8] EU/mL for NVX-CoV2373, NVX-CoV2515, and the bivalent
222	vaccine, respectively (Figure 1). A somewhat similar pattern of response was seen using the
223	ancestral strain anti-spike IgG assay, with GMEUs of 53,531.1 [46,055.5, 62,220.1], 40,423.4

224 [35,120.0, 46,527.7] and 42,783.9 [37,649.7, 48,618.1] EU/mL for NVX-CoV2373, NVX-

- 225 CoV2515, and the bivalent vaccine, respectively (Figure 1).
- 226 Pseudovirus neutralization GMTs against the Omicron BA.1 sublineage were the highest in
- 227 participants receiving NVX-CoV2515, followed by those receiving the bivalent vaccine and
- 228 NVX-CoV2373 (ID₅₀ titers [95% CI] of 816.1 [639.9, 1040.7], 562.0 [439.6, 718.6], and 449.1
- [345.3, 584.2], respectively) (Figure 1). ID₅₀ GMTs for the ancestral strain pseudovirus
- 230 neutralization assay were somewhat lower in participants receiving NVX-CoV2515 and the
- 231 bivalent vaccine compared with NVX-CoV2373 (ID₅₀ titers [95% CI] of 1181.1 [976.6, 1428.3],
- 232 1195.1 [1012.1, 1411.2], and 1473.0 [1227.1, 1768.3], respectively) (**Table 2**).

233 Per Protocol Analysis Set 2:

- 234 Microneutralization assay GMTs against the Omicron BA.1 sublineage for participants in the
- 235 PP2 population, which included those with a positive baseline SARS-CoV-2 result, were the
- highest in participants receiving NVX-CoV2515, followed by those receiving the bivalent
- 237 vaccine and NVX-CoV2373 (MN₅₀ titers [95% CI] of 318.2 [269.8, 375.3], 252.7 [213.1, 299.7],
- and 218.1 [186.0, 255.7], respectively) (Figure 2). NVX-CoV2515 induced a non-inferior SRR
- against the Omicron BA.1 subvariant virus versus NVX-CoV2373 (54.3% [134/247] vs 32.0%
- 240 [78/244]) at Day 14, with similar results on Day 28 (Table 3). MN₅₀ GMTs for the ancestral
- strain microneutralization assay were somewhat lower in participants receiving NVX-CoV2515
- compared with the bivalent and NVX-CoV2373 vaccines (MN₅₀ titers [95% CI] of 2206.2
- 243 [1910.0, 2548.4], 2544.7 [2194.5, 2950.9], and 2702.0 [2347.9, 3109.4], respectively) (**Table 3**).
- 244 Similar to the PP1 population, anti-spike IgG assay data indicate the highest levels of BA.1 IgG
- are achieved with vaccination using NVX-CoV2373, indicating cross-reactivity with the
- Omicron BA.1 sublineage (Table 3). Anti-spike IgG GMEUs [95% CI] for the BA.1 assay were

247 49,727.7 [44,331.1, 55,781.1], 42,835.5 [37,883.8, 48,434.4], and 42,462.1 [37,628.9, 47,916.2]

EU/mL for NVX-CoV2373, NVX-CoV2515, and the bivalent vaccine, respectively (Figure 2).

A relatively similar pattern of response was seen using the ancestral strain anti-spike IgG assay,

250 with GMEUs of 90,962.2 [81,361.1, 101,696.2], 78,191.9 [69,489.1, 87,984.5], and 71,076.4

251 [63,012.1, 80,172.9] EU/mL for NVX-CoV2373, bivalent vaccine, and NVX-CoV2515,

respectively (Figure 2).

253 Safety Analysis Set:

254 The overall rates of solicited local and systemic reactions reported within 7 days after booster

255 vaccination were similar across all 3 investigational products (Figure 3). Rates of solicited local

256 events of any grade were 69.3% (196/286; Grade 3+: 1.8% [5/286]), 71.0% (193/274; 0.4%

257 [1/274]), and 64.6% (173/269; 1.1% [3/269] for NVX-CoV2515, NVX-CoV2373, and the

bivalent vaccine, respectively). No Grade 4 solicited local treatment-emergent adverse events

259 (TEAEs) were reported. Local reactions were generally short-lived, with a median duration of

260 1.0 day for all events except tenderness (2.0 days). Solicited systemic reactions were similar

across the groups with event rates [Grade 3+ rates] of 62.2% [7.3%], 58.1% [3.7%], and 61.9%

262 [3.0%] for NVX-CoV2515, NVX-CoV2373, and the bivalent vaccine, respectively. There was

263 one Grade 4 solicited systemic TEAE (fever) reported in the NVX-CoV2515 group. Solicited

264 systemic reactions were transient in nature, with a median duration of 1.0 day for all events

265 except fatigue, which had a median duration of 2.0 days.

266 Through 28 days after vaccination, unsolicited TEAEs occurred in 34.3% (98/286), 38.0%

267 (104/274), and 33.8% (91/269) of participants in the NVX-CoV2515, NVX-CoV2373, and the

bivalent vaccine groups, respectively (Table 4). Unsolicited serious TEAEs occurred in 0.3%

269 (1/286) and 0.4% (1/274) of participants in the NVX-CoV2515 and NVX-CoV2373,

270 respectively, though neither of these events were reported as vaccine related. No unsolicited

- 271 serious TEAEs occurred in the bivalent vaccine group. There were no treatment-related
- 272 medically attended adverse events (MAAEs) or potential immune-mediated medical conditions
- 273 (PIMMCs) in any vaccine group.

274 **Discussion**

- 275 In this report, we describe the first immunogenicity and safety data for Omicron-specific (NVX-
- 276 CoV2515) and bivalent SARS-CoV-2 rS protein subunit vaccines. These results are from an
- 277 interim analysis of an ongoing phase 3, randomized, observer-blinded, clinical trial in
- 278 participants who previously received a regimen of 3 doses of prototype mRNA vaccine.
- 279 After participants received a single booster dose of either NVX-CoV2515, NVX-CoV2373, or
- 280 the bivalent vaccine (NVX-CoV2515 + NVX-CoV2373), immunogenicity assessments—
- 281 microneutralization (MN₅₀), anti-S IgG (GMEU), and pseudovirus neutralization (ID₅₀) assays—
- were analyzed on Days 14 and 28 post-vaccination.
- 283 The primary endpoint analysis demonstrated that the Omicron BA.1-specific vaccine, NVX-
- 284 CoV2515, produced a superior neutralizing antibody response (MN₅₀) against the Omicron BA.1
- subvariant when compared with the prototype vaccine, NVX-CoV2373, and met the non-
- 286 inferiority criterion for SRR versus NVX-CoV2373 at Day 14 following booster administration,
- 287 thereby successfully achieving the study's primary objective.
- Although NVX-CoV2515 demonstrated superior MN₅₀ titers against the Omicron BA.1 strain,
- when compared with NVX-CoV2373, this trend did not persist through all assay types. NVX-
- 290 CoV2515, NVX-CoV2373, and the bivalent vaccine elicited similar MN₅₀ and pseudovirus ID₅₀
- 291 responses against the ancestral strain. Trends with the MN₅₀ assays were maintained both in

292 participants with no evidence of previous infection (PP1) and in participants with evidence of 293 previous infection, as determined by anti-NP status at baseline (PP2). With regard to prevention 294 of severe disease and hospitalization due to COVID-19, both neutralizing and non-neutralizing 295 antibodies play a role in vaccine efficacy [17]. Thus, lower titers for neutralizing antibodies do 296 not necessarily indicate lower vaccine efficacy. Overall, these assays revealed no consistent 297 immunogenic differences between the prototype and the bivalent vaccine. 298 In a recent study, the immunogenicity of the mRNA-1273.214 bivalent vaccine (ancestral SARS-299 CoV-2 strain + Omicron BA.1) was investigated in individuals who previously received three 300 doses of the prototype mRNA-1273 vaccine [11]. Compared with individuals who received the 301 prototype mRNA.1273 vaccine as a fourth booster dose, those who received mRNA.1273.214 as 302 a fourth dose exhibited higher binding antibody responses against Omicron BA.1 and Omicron 303 BA.4/5 variants, resulting in the acknowledged superiority of mRNA.1273.214 to the mRNA-304 1273 prototype vaccine. An additional study conducted with the same bivalent mRNA vaccine 305 showed that both the Omicron-BA.1-monovalent mRNA-1273.529 and bivalent mRNA-306 1273.214 vaccines elicited superior neutralizing antibody responses against Omicron BA.1 307 compared with the prototype mRNA-1273 vaccine [18]. 308 After receiving a single dose of either NVX-CoV2515, NVX-CoV2373, or bivalent vaccine, 309 participant sera from each of the 3 study groups achieved anti-Spike IgG antibody concentrations 310 against the ancestral SARS-CoV-2 strain that were previously associated with vaccine efficacy 311 levels of 88%-95% in pivotal phase 3 studies of the prototype vaccine [6,19]. Anti-Spike IgG 312 antibody responses using the Omicron BA.1-specific assay were balanced across the 3 study 313 groups, regardless of baseline status of confirmed prior infection, displaying similar benefits of 314 NVX-CoV2515, the bivalent vaccine, and the prototype vaccine. The consistent anti-Spike IgG

315 responses (agnostic of strain) suggest the development of broadly cross-reacting IgG antibodies

316 following administration of SARS-CoV-2 rS protein subunit vaccines, either as the prototype,

317 BA.1 variant, or bivalent vaccine.

- 318 Overall, the variant specific vaccine (NVX-CoV2515) induced a superior neutralizing antibody
- 319 response against the Omicron BA.1 subvariant when compared with the prototype vaccine,
- 320 NVX-CoV2373. The NVX-CoV2515 and bivalent SARS-CoV-2 rS protein subunit vaccines
- 321 demonstrated similar immunogenicity 14 days post-vaccination, with no added benefits when
- 322 compared with the prototype product (NVX-CoV2373) across several ancestral strain- and
- 323 Omicron BA.1–specific immunoassays. Immunogenicity results at Day 28 were generally similar
- to those at Day 14.
- 325 The PP2 population assessed in this study most accurately represents a real-world population in
- 326 which previous SARS-CoV-2 infection is not uncommon. In Australia as of November 2022, at
- 327 least 66% of the population were estimated to had been previously infected by SARS-CoV-2
- 328 [20]. Anti-S IgG antibody responses against the Omicron BA.1 subvariant for the PP2 population
- 329 were generally 1.5- to 2-fold greater than those for the PP1 population. These results align with
- 330 studies that assessed immune responses in both participants with and without previous SARS-
- 331 CoV-2 infection that showed that neutralization of subvariant SARS-CoV-2 strains was higher
- after a booster with bivalent mRNA vaccine than after a booster dose with prototype mRNA
- 333 vaccine [10,11].
- 334 The incidence of solicited local and systemic reactogenicity reported in this study was consistent
- 335 with previous studies of NVX-CoV2373, with pain/tenderness being the most common local
- 336 solicited AE and fatigue being the most common solicited systemic AE [6,21]. Incidence rates
- 337 for all local and systemic events were similar across all vaccine groups.

Incidences of unsolicited TEAEs and serious AEs were also unremarkable with respect to prior
research on the prototype vaccine, and there were no reports of related MAAEs, PIMMCs, or
SAEs. Collectively, these data were consistent with the safety profile of other variant-specific
SARS-CoV-2 rS protein subunit vaccines, bivalent combination, or with use as a heterologous
booster in combination with mRNA vaccines.

343 Our study was subject to certain limitations. As these results are from an ongoing phase 3 study 344 conducted with a limited sample size, clinical efficacy of the booster dose was not evaluated. 345 Safety follow-up in this study, at present, is also limited to 28 days. Furthermore, it remains to be 346 seen if the conclusions based on the prototype versus variant-specific vaccines in this study can 347 be extrapolated to newer strains or newer vaccines. For example, in a recent study comparing the 348 neutralization activity of a bivalent BA.4/5 BNT162b2 vaccine to the prototype BNT162b2 349 vaccine against newly emerged Omicron sublineages descended from BA.2 and BA.4/BA.5 in 350 persons who previously received three doses of BNT162b2, the bivalent BA.4/5 vaccine was 351 more immunogenic than the original BNT162b2 monovalent vaccine against circulating 352 Omicron sublineages [10]. Additionally, newer Omicron subvariants such as BQ and XBB show 353 marked evasion of vaccine-induced neutralization and evasion from monoclonal antibodies with 354 known neutralization capability against the original Omicron variant [22]. Therefore, responses to the Omicron BA.5 variant after immunization with NVX-CoV2515, NVX-CoV2373, or 355 356 bivalent vaccine, and the effect of a subsequent booster dose at 3 months, will be addressed in 357 future work, given that BA.5 is more closely related phylogenetically to XBB and BO than to the 358 ancestral strain.

In conclusion, the variant-specific vaccine NVX-CoV2515 demonstrated superior neutralizing
 response against the matched Omicron BA.1 subvariant virus. The prototype and bivalent

- 361 vaccines also induced robust immune responses to ancestral and Omicron subvariant strains of
- 362 SARS-CoV-2 when administered as a fourth dose. Moreover, the safety profile of updated
- 363 variant-specific SARS-CoV-2 rS protein subunit vaccines remained consistent with the prototype
- 364 vaccine when administered as a heterologous booster dose following 3 vaccinations with mRNA
- 365 vaccines.
- 366

367 Funding

368 This work was supported by Novavax, Inc.

369 Acknowledgments

- 370 We thank all the study participants who volunteered for this study. This study was funded by
- 371 Novavax, Inc. Editorial support was provided by Kelly Cameron, PhD, and Amanda Cox, PhD,
- 372 of Ashfield MedComms (New York, USA), an Inizio company, supported by Novavax, Inc.

373 Contributors

- 374 RMM, KA, JSP, and NP were involved in the study design, data collection, and interpretation.
- 375 SG performed the statistical analyses. All authors reviewed, commented on, and approved this
- 376 manuscript prior to submission for publication. The authors were not precluded from accessing
- 377 data in the study, and they accept responsibility to submit the manuscript for publication.

Declaration of interests

- 379 CB, EJR, WW, JSP, SCC, MZ, RK, NP, AB, AM, JS, GS, IC, GMG, RW, and RMM are current
- 380 or former Novavax employees and as such receive or received a salary for their work, and may
- 381 hold Novavax stock. OC and TMP act as investigators at Novatrials on clinical trials and have
- 382 not received personal financial payment from Novavax. AMN acts an investigator at AusTrials
- 383 on clinical trials of COVID-19 and other vaccines sponsored by vaccine manufacturers,
- 384 including Pfizer, GlaxoSmithKline, Novavax, Seqirus and Moderna. He receives no personal
- 385 financial payment for this work. KC acts as an investigator at Emeritus Research and has not
- 386 received any personal financial payment from Novavax. RM acts as an investigator at Paratus
- 387 Clinical Research and has not received any personal financial payment from Novavax. MB has
- 388 received payment or honoraria as well as support for meeting attendance and/or travel from

- 389 Gilead Sciences and ViiV Healthcare, and has received research funding from Gilead Sciences,
- 390 ViiV Healthcare, GlaxoSmithKline, Merck & Co, Eli Lilly, Amgen, Pfizer, Bristol-Myers
- 391 Squibb, Novartis, and Sanofi. He has also participated on a data safety monitoring board or
- 392 advisory board for Gilead Sciences, ViiV Healthcare, and Cymra. MA, PG, and SD report no
- 393 conflicts of interest.
- **Data sharing**
- 395 Study information is available at <u>https://clinicaltrials.gov/ct2/show/NCT05372588</u>, and requests
- 396 will be considered.

397 **References**

398	1.	Marks P. Coronavirus (COVID-19	Update:	FDA R	Recommends	Inclusion	of Omicron
570	1.	Marks I. Corona mus (, opune.	I D/I I	coommentas	merusion	or onneron

- 399 BA.4/5 Component for COVID-19 Vaccine Booster Doses: U.S. Food & Drug
- 400 Administration; 2022. Available from: <u>https://www.fda.gov/news-events/press-</u>
- 401 <u>announcements/coronavirus-covid-19-update-fda-recommends-inclusion-omicron-ba45-</u>
- 402 <u>component-covid-19-vaccine-booster</u>
- 403 2. Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and
- 404 definitions [updated 2023 March 20; cited 2023 May 5]. Available from:
- 405 <u>https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-</u>
- 406 <u>classifications.html#anchor_1632154493691</u>
- 407 3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
 408 Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615.
- 409 4. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-
- 410 CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416.
- 411 5. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19
 412 Vaccine. N Engl J Med. 2021 Sep 23;385(13):1172-1183.
- 413 6. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and Safety of NVX-CoV2373 in Adults
 414 in the United States and Mexico. N Engl J Med. 2022 Feb 10;386(6):531-543.
- 415 7. Tartof SY, Slezak JM, Puzniak L, et al. BNT162b2 vaccine effectiveness against SARS-
- 416 CoV-2 omicron BA.4 and BA.5. Lancet Infect Dis. 2022 Dec;22(12):1663-1665.
- 417 8. Kurhade C, Zou J, Xia H, et al. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-
- 418 CoV-2 by 3 doses of BNT162b2 vaccine. Nat Commun. 2022 Jun 23;13(1):3602.

419	9.	Tseng HF, Ackerson BK, Bruxvoort KJ, et al. Effectiveness of mRNA-1273 vaccination
420		against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat
421		Commun. 2023 Jan 12;14(1):189.
422	10.	Zou J, Kurhade C, Patel S, et al. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2,
423		BQ.1.1, and XBB.1 with Bivalent Vaccine. N Engl J Med. 2023 Mar 2;388(9):854-857.
424	11.	Chalkias S, Harper C, Vrbicky K, et al. A Bivalent Omicron-Containing Booster Vaccine
425		against Covid-19. N Engl J Med. 2022 Oct 6;387(14):1279-1291.
426	12.	US Food and Drug Administration (FDA). FDA Briefing Document: Vaccines and
427		Related Biological Products Advisory Committee Meeting. Selection of Strain(s) to be
428		Included in the Periodic Updated COVID-19 Vaccines for the 2023-2024 Vaccination
429		Campaign. 2023 June 15.
430	13.	World Health Organization (WHO). Statement on the antigen composition of COVID-19
431		vaccines 2023 May 18 [cited 2023 June 27]. Available from:
432		https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-
433		covid-19-vaccines
434	14.	European Medicines Agency (EMA). EMA and ECDC statement on updating COVID-19
435		Vaccines to target new SARS-CoV-2 virus variants 2023 June 6 [cited 2023 June 27].
436		Available from: https://www.ema.europa.eu/en/news/ema-ecdc-statement-updating-
437		covid-19-vaccines-target-new-sars-cov-2-virus-
438		variants#:~:text=In%20line%20with%20the%20outcome,other%20parts%20of%20the%
439		<u>20world</u> .

440	15.	Madhi SA, Moodley D, Hanley S, et al. Immunogenicity and safety of a SARS-CoV-2
441		recombinant spike protein nanoparticle vaccine in people living with and without HIV-1
442		infection: a randomised, controlled, phase 2A/2B trial. Lancet HIV. 2022 May;9(5):e309-
443		e322.
444	16.	Huang Y, Borisov O, Kee JJ, et al. Calibration of two validated SARS-CoV-2
445		pseudovirus neutralization assays for COVID-19 vaccine evaluation. Sci Rep. 2021 Dec
446		14;11(1):23921.
447	17.	Bates TA, Lu P, Kang YJ, et al. BNT162b2-induced neutralizing and non-neutralizing
448		antibody functions against SARS-CoV-2 diminish with age. Cell Rep. 2022 Oct
449		25;41(4):111544.
450	18.	Lee IT, Cosgrove CA, Moore P, et al. A Randomized Trial Comparing Omicron-
451		Containing Boosters with the Original Covid-19 Vaccine mRNA-1273. medRxiv. 2023.
452	19.	Fong Y, Huang Y, Benkeser D, et al. Immune correlates analysis of the PREVENT-19
453		COVID-19 vaccine efficacy clinical trial. Nat Commun. 2023 Jan 19;14(1):331.
454	20.	Australian COVID-19 Serosurveillance Network. Seroprevalence of SARS-CoV-2-
455		specific antibodies among Australian blood donors: Round 3 update. [updated 03
456		November 2022; cited 2023 14 April]. Available from:
457		https://kirby.unsw.edu.au/sites/default/files/COVID19-Blood-Donor-Report-Round3-
458		Aug-Sep-2022.pdf
459	21.	Mallory RM, Formica N, Pfeiffer S, et al. Safety and immunogenicity following a
460		homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-

461 CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.

- 462 Lancet Infect Dis. 2022 Nov;22(11):1565-1576.
- 463 22. Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-
- 464 CoV-2 BQ and XBB subvariants. Cell. 2023 Jan 19;186(2):279-286 e8.

465

466 **Tables and Figures**

Table 1. Demographics and baseline disease characteristics (Safety Analysis Set^a)

			Bivalent
Devenuedant	NVX-CoV2515	NVX-CoV2373	(NVX-CoV2373 +
Parameters	N = 286	N = 274	NVX-CoV2515)
			N = 269
Age (years)		1	
Mean (SD)	40.4 (12.1)	40.1 (11.5)	39.9 (12.4)
Median	42.0	41.0	41.0
Min–max	18–64	18–64	18–64
Sex, n (%)		1 1	
Male	133 (46.5)	131 (47.8)	118 (43.9)
Female	153 (53.5)	143 (52.2)	151 (56.1)
Race, n (%)		1 1	
White	233 (81.5)	215 (78.5)	220 (81.8)
Black or African American	0	2 (0.7)	0
Aboriginal Australian	2 (0.7)	1 (0.4)	2 (0.7)
Native Hawaiian or Other Pacific Islander	1 (0.3)	0	1 (0.4)
Asian	37 (12.9)	45 (16.4)	39 (14.5)
Mixed Origin	5 (1.7)	3 (1.1)	1 (0.4)
Other	8 (2.8)	8 (2.9)	6 (2.2)
Not Reported	0	0	0
Ethnicity, n (%)		11	
Australian	252 (88.1)	236 (86.1)	233 (86.6)
Aboriginal/Torres Strait Islanders	4 (1.4)	3 (1.1)	2 (0.7)
Hispanic or Latino	6 (2.1)	8 (2.9)	6 (2.2)
Not reported	12 (4.2)	15 (5.5)	17 (6.3)

Unknown	10 (3.5)	11 (4.0)	9 (3.3)
Missing	2 (0.7)	1 (0.4)	2 (0.7)
BMI (kg/m ²)			
n	284	270	267
Mean (SD)	28.07 (6.4)	28.01 (5.3)	27.40 (5.7)
Median	26.9	27.5	26.3
Min-max	18.1–55.8	17.4-47.2	17.7–50.1
BMI (kg/m ²) category, n (%)			
Underweight (<18.0)	0	3 (1.1)	2 (0.7)
Normal (18.0–24.9)	106 (37.1)	75 (27.4)	104 (38.7)
Overweight (25.0–29.9)	87 (30.4)	108 (39.4)	90 (33.5)
Obese (≥30.0)	91 (31.8)	84 (30.7)	71 (26.4)
Missing	2 (0.7)	4 (1.5)	2 (0.7)
Regimen of previous COVID-19 vaccine,	n (%)		
Modema	0	2 (0.7)	5 (1.9)
Pfizer-BioNTech	213 (74.5)	214 (78.1)	200 (74.3)
Mixed	73 (25.5)	58 (21.2)	64 (23.8)
Moderna-Moderna-Pfizer	1 (0.3)	1 (0.4)	0
Moderna-Pfizer-Pfizer	2 (0.7)	0	1 (0.4)
Moderna-Pfizer-Moderna	0	0	0
Pfizer-Pfizer-Moderna	70 (24.5)	56 (20.4)	63 (23.4)
Pfizer-Moderna-Moderna	0	1 (0.4)	0
Pfizer-Moderna-Pfizer	0	0	0
Previous COVID-19, n (%)	I	1	
Yes	18 (6.3)	19 (6.9)	17 (6.3)
No	268 (93.7)	255 (93.1)	252 (93.7)
Qualitative anti-N, n (%)			

Negative	141 (49.3)	133 (48.5)	135 (50.2)
PCR, n (%)			
Positive	11 (3.8)	12 (4.4)	14 (5.2)
Negative	275 (96.2)	262 (95.6)	255 (94.8)
Anti-N / PCR, n (%) ¹			
Positive	149 (52.1)	145 (52.9)	137 (50.9)
Negative	137 (47.9)	129 (47.1)	132 (49.1)
Time between last previous COVID	D-19 vaccine and booster dose of study	vaccine (days)	
Mean (SD)	178.2 (38.5)	182.4 (36.4)	178.7 (36.6)
Median	177.0	182.0	180.0
Min-max	84-440	91–329	77–313
nterval between last previous COV	/ID-19 vaccine and booster dose of stud	dy vaccine, n (%)	
<90 days	1 (0.3)	0	1 (0.4)
90–120 days	15 (5.2)		
	15 (5.2)	15 (5.5)	18 (6.7)
>120–150 days	43 (15.0)	15 (5.5) 35 (12.8)	18 (6.7) 36 (13.4)
-			
>120–150 days	43 (15.0)	35 (12.8)	36 (13.4)
>120–150 days >150–180 days	43 (15.0) 98 (34.3)	35 (12.8) 81 (29.6)	36 (13.4) 81 (30.1)
>120–150 days >150–180 days >180–210 days	43 (15.0) 98 (34.3) 87 (30.4)	35 (12.8) 81 (29.6) 97 (35.4)	36 (13.4) 81 (30.1) 94 (34.9)
>120–150 days >150–180 days >180–210 days >210–240 days	43 (15.0) 98 (34.3) 87 (30.4) 26 (9.1)	35 (12.8) 81 (29.6) 97 (35.4) 32 (11.7)	36 (13.4) 81 (30.1) 94 (34.9) 25 (9.3)
>120–150 days >150–180 days >180–210 days >210–240 days >240–270 days	43 (15.0) 98 (34.3) 87 (30.4) 26 (9.1) 10 (3.5)	35 (12.8) 81 (29.6) 97 (35.4) 32 (11.7) 9 (3.3)	36 (13.4) 81 (30.1) 94 (34.9) 25 (9.3) 11 (4.1)
>120–150 days >150–180 days >180–210 days >210–240 days >240–270 days >270–300 days	43 (15.0) 98 (34.3) 87 (30.4) 26 (9.1) 10 (3.5) 4 (1.4)	35 (12.8) 81 (29.6) 97 (35.4) 32 (11.7) 9 (3.3) 2 (0.7)	36 (13.4) 81 (30.1) 94 (34.9) 25 (9.3) 11 (4.1) 1 (0.4)

Abbreviations: anti-N = anti-nucleocapsid; BMI = body mass index; COVID-19 = coronavirus disease 2019; max = maximum; min = minimum; NVX-CoV2515 = 5 μ g SARS-CoV-2 rS with 50 μ g Matrix-M adjuvant; NVX-CoV2373 = 5 μ g SARS-CoV-2 rS with 50 μ g Matrix-M adjuvant; NVX-CoV2373 + NVX-CoV2515 = 5 μ g SARS-CoV-2 rS with 50 μ g Matrix-M adjuvant (total); PCR = polymerase chain reaction; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SARS-CoV-2 rS = severe acute respiratory syndrome

coronavirus 2 recombinant spike protein nanoparticle vaccine; SD = standard deviation.

^aParticipants in the safety analysis set are counted according to the treatment received to accommodate for

treatment errors.

Note: Age was calculated at the time of informed consent.

Note: n for continuous parameters represents the number of participants with non-missing values for that

parameter.

Note: BMI was calculated as weight (kg) divided by squared height (m). Percentages were based on the Safety

Analysis Set within each treatment and overall.

1. Participants with either anti-N or PCR are reported.

467

Table 2. Summary of serum microneutralization titers, anti-rS IgG antibody concentrations, and pseudovirus neutralization titers against the

Ancestral and Omicron BA.1 variant strain following a heterologous 4th booster dose (PP1 Analysis Set)

	NVX-CoV2515		NVX-C	oV2373	Biva	lent
Vaccine Group	N =	N = 126		119	N = 118	
_	Ancestral	BA.1	Ancestral	BA.1	Ancestral	BA.1
Microneutralization titers (MI	N ₅₀)					
Day 0 (baseline) ^a						
n1	126	126	119	119	114	114
Median	640.0	20.0	640.0	20.0	480.0	20.0
Min, max	20–5120	10–320	20–10240	10–1280	40–5120	10–320
GMT (MN ₅₀)	457.6	25.2	486.7	27.9	431.1	26.0
95% CI ^b	378.2, 553.5	21.5, 29.5	393.3, 602.3	22.9, 33.9	359.4, 517.0	21.8, 30.9
Day 14						
nl	124	124	116	116	113	113
Median	1280.0	160.0	1280.0	80.0	1280.0	80.0
Min, max	80–10240	10-1280	160-40960	10–1280	80–10240	10–1280
GMT (MN ₅₀)	1076.3	130.8	1442.5	83.9	1319.9	97.9
95% CI ^b	908.4, 1275.4	109.2, 156.7	1192.4, 1745.0	69.6, 101.2	1120.1, 1555.3	81.3, 117.9
n2	124	124	116	116	113	113
GMFR referencing Day 0	2.4	5.2	3.0	3.0	3.1	3.7
95% CI ^b	2.0, 2.8	4.4, 6.1	2.5, 3.5	2.6, 3.6	2.6, 3.6	3.2, 4.4
SRR ≥4-fold increase, [°]	54/124 (43.5)	91/124 (73.4)	57/116 (49.1)	59/116 (50.9)	64/113 (56.6)	74/113 (65.5)
n3/n2 (%)	57/127 (75.5)) II I27 (15.7)	5//110 (19.1)	55,110 (50.5)	01/115 (50.0)	(03.3)

95% CI ^d	34.7, 52.7	64.7, 80.9	39.7, 58.6	41.4, 60.3	47.0, 65.9	56.0, 74.2
Day 28						
n1	116	116	110	110	102	102
Median	1280.0	160.0	1280.0	80.0	1280.0	80.0
Min, max	40–10240	10-2560	80-40960	10-2560	160–10240	10-640
GMT (MN ₅₀)	960.8	122.3	1442.8	77.5	1087.4	87.4
95% CI ^b	798.0, 1156.9	101.0, 148.0	1188.1, 1752.1	63.1, 95.3	906.5, 1304.3	72.0, 106.1
n2	116	116	110	110	102	102
GMFR referencing Day 0	2.0	4.8	3.0	2.9	2.4	3.3
95% CI ^b	1.7, 2.4	4.1, 5.7	2.5, 3.6	2.4, 3.6	2.1, 2.8	2.8, 3.8
SRR ≥4-fold increase,° n3/n2 (%)	37/116 (31.9)	86/116 (74.1)	54/110 (49.1)	52/110 (47.3)	42/102 (41.2)	56/102 (54.9)
95% CI ^d	23.6, 41.2	65.2, 81.8	39.4, 58.8	37.7, 57.0	31.5, 51.4	44.7, 64.8
Serum anti-rS IgG antibodi	es (EU/mL)					
Day 0 (baseline) ^a						
nl	126	126	118	118	118	118
Median	18549.0	9709.0	18415.0	8654.0	16869.5	9021.5
Min, max	2915–146257	652–64111	2232–1002823	864–249167	2279–212765	814–117381
GMEU (EU/mL)	18773.6	9117.3	20168.6	9770.2	17803.1	8598.7
95% CI ^e	16206.3, 21747.5	7796.7, 10661.7	16760.8, 24269.2	8107.6, 11773.8	15264.7, 20763.6	7326.9, 10091.1
Day 14	1		1	1	1	
nl	124	124	115	115	116	116
Median	42975.0	26627.5	55183.0	32732.0	40265.0	23036.0

Min, max	3973-399697	1623–234270	5604-518336	2097–358950	6811–232384	3178–233435
GMEU (EU/mL)	40423.4	24174.8	53531.1	30170.9	42783.9	23045.5
95% CI ^e	35120.0, 46527.7	20943.6, 27904.6	46055.5, 62220.1	25663.7, 35469.6	37649.7, 48618.1	20113.5, 26404.8
n2	124	124	115	115	116	116
GMFR referencing Day 0	2.2	2.7	2.7	3.1	2.4	2.7
95% CI ^e	1.9, 2.4	2.4, 3.0	2.3, 3.0	2.7, 3.5	2.1, 2.7	2.4, 3.0
SRR ≥4-fold increase, ^f n3/n2 (%)	17/124 (13.7)	31/124 (25.0)	31/115 (27.0)	41/115 (35.7)	23/116 (19.8)	29/116 (25.0)
95% CI ^d	8.2, 21.0	17.7, 33.6	19.1, 36.0	26.9, 45.1	13.0, 28.3	17.4, 33.9
Day 28						
nl	116	116	110	110	108	108
Median	41916.5	25590.5	56963.5	32178.0	39302.5	21025.0
Min, max	3572-338495	1595–183367	5668-675805	1606–361845	6763–340211	2699–256572
GMEU (EU/mL)	40833.4	22732.1	54598.2	28448.6	41070.0	21772.1
95% CI ^e	35196.6, 47373.1	19381.6, 26661.8	46668.3, 63875.5	24062.8, 33633.8	35625.2, 47346.9	18753.6, 25276.5
n2	116	116	110	110	108	108
GMFR referencing Day 0	2.1	2.5	2.8	3.0	2.3	2.5
95% CI°	1.9, 2.4	2.2, 2.8	2.4, 3.2	2.6, 3.4	2.0, 2.5	2.2, 2.8
SRR ≥4-fold increase, ^f n3/n2 (%)	19/116 (16.4)	27/116 (23.3)	33/110 (30.0)	35/110 (31.8)	17/108 (15.7)	22/108 (20.4)
95% CI ^d	10.2, 24.4	15.9, 32.0	21.6, 39.5	23.3, 41.4	9.4, 24.0	13.2, 29.2
seudovirus neutralization tit	ers (ID ₅₀)	1	1	1	1	
Day 0 (baseline) ^a						
nl	111	111	105	105	105	105

Median	584.0	116.0	431.0	124.0	476.0	96.0
Min, max	20-4746	20–2937	20–26040	20–7900	50-7541	20–5317
GMT (ID ₅₀)	496.7	99.6	517.1	103.6	483.3	89.2
95% CI ^b	401.0, 615.2	77.1, 128.8	409.3, 653.1	77.9, 137.8	400.7, 583.0	68.2, 116.9
Day 14		<u> </u>	11			
nl	110	110	102	102	103	103
Median	1341.0	930.5	1476.0	433.5	1084.0	496.0
Min, max	20–19256	20-30281	273–34712	20–15337	153–11739	20–6949
GMT (ID ₅₀)	1181.1	816.1	1473.0	449.1	1195.1	562.0
95% CI ^b	976.6, 1428.3	639.9, 1040.7	1227.1, 1768.3	345.3, 584.2	1012.1, 1411.2	439.6, 718.6
n2	110	110	102	102	103	103
GMFR referencing Day 0	2.4	8.2	2.9	4.4	2.5	6.3
95% CI ^b	2.0, 2.8	6.5, 10.5	2.5, 3.4	3.6, 5.5	2.2, 2.8	5.0, 7.9
SRR ≥4-fold increase,° n3/n2 (%)	21/110 (19.1)	81/110 (73.6)	25/102 (24.5)	48/102 (47.1)	25/103 (24.3)	68/103 (66.0)
95% CI ^d	12.2, 27.7	64.4, 81.6	16.5, 34.0	37.1, 57.2	16.4, 33.7	56.0, 75.1
Day 28						
nl	101	101	98	98	97	97
Median	1219.0	953.0	1390.0	425.5	1043.0	502.0
Min, max	20–15355	20–9668	20–26603	20–25073	154–9349	20–5474
GMT (ID ₅₀)	1085.8	661.6	1420.2	404.1	1106.1	502.1
95% CI ^b	891.5, 1322.4	509.7, 858.7	1141.9, 1766.2	305.4, 534.7	937.7, 1304.8	393.7, 640.4
n2	101	101	98	98	97	97
GMFR referencing Day 0	2.2	6.7	2.9	4.1	2.3	5.6

95% CI ^b	1.9, 2.6	5.2, 8.7	2.3, 3.5	3.2, 5.3	2.0, 2.6	4.4, 7.0
SRR ≥4-fold increase, ^c	20/101 (19.8)	69/101 (68.3)	29/98 (29.6)	46/98 (46.9)	18/97 (18.6)	58/97 (59.8)
n3/n2 (%)						
95% CI ^d	12.5, 28.9	58.3, 77.2	20.8, 39.7	36.8, 57.3	11.4, 27.7	49.3, 69.6

Abbreviations: CI = confidence interval; GMEU= geometric mean ELISA units; GMFR = geometric mean fold rise; GMT = geometric mean titer;

 ID_{50} = inhibitory dilution with a 50% concentration; Max = maximum; Min = minimum; N = number of participants in the assay-specific analysis Set; n1 = number of participants within each visit with non-missing data; n2 = number of participants with non-missing data at both visits of interest; n3 = number of participants who reported \geq 4-fold increase with percentages calculated based on n2 as the denominator; LLOQ = lower limit of quantitation; SRR = seroresponse rate.

^aBaseline was defined as the last non-missing assessment prior to first vaccination. ^bThe 95% CI for GMT and GMFR were calculated based on the tdistribution of the log-transformed values then back transformed to the original scale for presentation. ^cThe SRR was defined as percentage of participants at each post vaccination visit with a titer \geq 4-fold rise in MN₅₀ or ID₅₀ level. ^dThe 95% CI for SRR was calculated using the exact Clopper-Pearson method. ^cThe 95% CI for GMEU and GMFR were calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation. ^fThe SRR was defined as percentage of participants at each post vaccination visit with a titer \geq 4-fold rise in anti-S IgG antibody level.

Note: Values less than LLOQ were replaced by $0.5 \times \text{LLOQ}$

Table 3. Summary of serum microneutralization titers, anti-rS IgG antibody concentrations, and pseudovirus neutralization titers against the

Ancestral and Omicron BA.1 variant strain following a heterologous 4th booster dose (PP2 Analysis Set)

Vaccine Group	NVX-CoV2515 N = 286		NVX-C	oV2373	Bivalent	
			N = 274		N = 269	
	Ancestral	BA.1	Ancestral	BA.1	Ancestral	BA.1
Microneutralization titers (MN	50)					
Day 0 (baseline) ^a						
n1	255	255	250	250	236	236
Median	1280.0	160.0	1280.0	160.0	1280.0	160.0
Min-max	20-40960	10–2560	20-40960	10–2560	40-81920	10–10240
GMT (MN ₅₀)	1151.3	97.3	1280.0	105.9	1232.0	106.1
95% CI ^b	973.6, 1361.4	79.6, 118.9	1078.1, 1519.7	86.4, 129.7	1026.0, 1479.5	85.8, 131.1
Day 14						
nl	247	247	244	244	232	232
Median	2560.0	320.0	2560.0	320.0	2560.0	320.0
Min-max	80-40960	10–5120	160-81920	10-2560	80–163840	10–5120
GMT (MN ₅₀)	2206.2	318.2	2702.0	218.1	2544.7	252.7
95% CI ^b	1910.0, 2548.4	269.8, 375.3	2347.9, 3109.4	186.0, 255.7	2194.5, 2950.9	213.1, 299.7
n2	247	247	244	244	232	232
GMFR referencing Day 0	1.9	3.3	2.1	2.1	2.1	2.4
95% CI ^b	1.8, 2.1	2.9, 3.7	1.9, 2.4	1.8, 2.3	1.9, 2.3	2.1, 2.7
SRR ≥4-fold increase,° n3/n2 (%)	79/247 (32.0)	134/247 (54.3)	80/244 (32.8)	78/244 (32.0)	83/232 (35.8)	95/232 (40.9)
95% CI ^d	26.2, 38.2	47.8, 60.6	26.9, 39.1	26.2, 38.2	29.6, 42.3	34.6, 47.6

ay 28						
nl	238	238	234	234	215	215
Median	2560.0	320.0	2560.0	160.0	2560.0	160.0
Min-max	40–20480	10–5120	80-40960	10–2560	160-81920	10–10240
GMT (MN ₅₀)	1918.8	284.8	2456.0	195.7	2144.0	218.7
95% CI ^b	1657.9, 2220.6	241.8, 335.4	2145.2, 2811.8	165.7, 231.2	1842.3, 2495.2	183.1, 261.3
n2	238	238	234	234	215	215
GMFR referencing Day 0	1.6	2.9	1.9	1.9	1.7	2.0
95% CI ^b	1.5, 1.8	2.5, 3.3	1.7, 2.2	1.6, 2.2	1.5, 1.9	1.8, 2.2
SRR ≥4-fold increase, ^c n3/n2 (%)	56/238 (23.5)	125/238 (52.5)	68/234 (29.1)	65/234 (27.8)	59/215 (27.4)	72/215 (33.5)
95% CI ^d	18.3, 29.4	46.0, 59.0	23.3, 35.3	22.1, 34.0	21.6, 33.9	27.2, 40.2
erum anti-rS IgG antibodies	(EU/mL)					
Day 0 (baseline) ^a						
n1	258	258	250	250	240	240
Median	45426.5	22876.0	54982.0	28832.0	49528.0	25602.0
Min-max	2915-576831	652–353367	2232–1002823	864-254105	2279–2034472	814–1121904
GMEU (EU/mL)	44166.7	21446.9	47810.6	23215.7	45047.6	22400.7
95% CI ^e	38369.6, 50839.6	18570.6, 24768.7	41184.3, 55503.1	19953.4, 27011.3	38572.8, 52609.1	19088.9, 26287.2
ay 14						
n1	250	250	244	244	235	235
Median	72765.5	41964.5	95097.0	50675.0	79657.0	43289.0
Min-max	3973-894339	1623-813679	5604-822744	2097–395875	6811–1656933	3178–1074179
GMEU (EU/mL)	71076.4	42835.5	90962.2	49727.7	78191.9	42462.1

95% CIe	63012.1, 80172.9	37883.8, 48434.4	81361.1, 101696.2	44331.1, 55781.1	69489.1, 87984.5	37628.9, 47916.2
n2	250	250	244	244	235	235
GMFR referencing Day 0	1.6	2.0	1.9	2.1	1.7	1.9
95% CI ^e	1.5, 1.7	1.8, 2.2	1.8, 2.1	2.0, 2.3	1.6, 1.9	1.7, 2.0
SRR ≥4-fold increase, ^f	10/250 (5.2)	24/250 (12.0)	25/244 (14.2)		22/225 (0.0)	20/225 (12.2)
n3/n2 (%)	18/250 (7.2)	34/250 (13.6)	35/244 (14.3)	42/244 (17.2)	23/235 (9.8)	29/235 (12.3)
95% CI ^d	4.3, 11.1	9.6, 18.5	10.2, 19.4	12.7, 22.5	6.3, 14.3	8.4, 17.2
ay 28		L			I	
nl	241	241	235	235	221	221
Median	72699.0	42388.0	92903.0	44971.0	70184.0	36642.0
Min-max	3572-755671	1595–543014	5668-675805	1606–375634	6763–2299922	2699–1217244
GMC (EU/mL)	70523.9	40044.9	87969.9	44756.4	73321.3	38315.6
95% CIe	62487.3, 79594.2	35308.6, 45416.6	78701.3, 98330.0	39966.0, 50120.9	64771.3, 83000.0	33783.4, 43455.9
n2	241	241	235	235	221	221
GMFR referencing Day 0	1.6	1.8	1.9	2.0	1.6	1.7
95% CI ^e	1.4, 1.7	1.7, 2.0	1.7, 2.0	1.8, 2.1	1.5, 1.8	1.6, 1.8
SRR ≥4-fold increase, ^f	10/241 (7.0)	20/241 (11 ()	24/225 (14.5)	27/225 (15 7)	17/221 (7.7)	22/221 (10.0)
n3/n2 (%)	19/241 (7.9)	28/241 (11.6)	34/235 (14.5)	37/235 (15.7)	17/221 (7.7)	22/221 (10.0)
95% CI ^d	4.8, 12.0	7.9, 16.4	10.2, 19.6	11.3, 21.0	4.5, 12.0	6.3, 14.7
seudovirus neutralization tite	ers (ID ₅₀)					
ay 0 (baseline) ^a						
nl	232	232	226	226	206	206
Median	1788.5	808.0	2224.5	962.0	1425.5	623.5
Min, max	20-39721	20-30397	20-28737	20–18494	50-81399	20-84031

GMT (ID ₅₀)	1491.2	548.4	1646.5	579.2	1476.4	491.9
95% CI ^b	1237.3, 1797.1	421.7, 713.2	1357.6, 1996.8	445.6, 752.8	1208.2, 1804.1	366.8, 659.6
ny 14						
n1	223	223	220	220	201	201
Median	2464.0	2202.0	3121.5	1690.5	2526.0	1677.0
Min, max	20–34131	20-41483	273–34859	20–23694	153–71353	20–72247
GMT (ID ₅₀)	2514.9	2071.5	3027.9	1390.3	2390.1	1480.4
95% CI ^b	2149.8, 2942.0	1701.1, 2522.5	2625.7, 3491.6	1134.6, 1703.8	2050.2, 2786.3	1202.8, 1822.1
n2	223	223	220	220	201	201
GMFR referencing Day 0	1.7	3.9	1.8	2.4	1.6	3.0
95% CI ^b	1.5, 1.9	3.3, 4.6	1.7, 2.0	2.1, 2.8	1.5, 1.8	2.5, 3.5
SRR ≥4-fold increase, ^c n3/n2 (%)	25/223 (11.2)	102/223 (45.7)	26/220 (11.8)	53/220 (24.1)	25/201 (12.4)	71/201 (35.3)
95% CI ^d	7.4, 16.1	39.1, 52.5	7.9, 16.8	18.6, 30.3	8.2, 17.8	28.7, 42.4
ay 28						
n1	214	214	212	212	191	191
Median	2445.0	2127.5	2875.0	1332.5	2193.0	1303.0
Min, max	20-45309	20–70894	20–31723	20–25073	154–168338	20–95088
GMT (ID ₅₀)	2411.6	1918.0	2716.9	1195.7	2236.0	1272.4
95% CI ^b	2055.6, 2829.2	1558.2, 2361.0	2340.0, 3154.5	974.9, 1466.6	1909.8, 2617.9	1033.5, 1566.6
n2	214	214	212	212	191	191
GMFR referencing Day 0	1.6	3.4	1.7	2.1	1.5	2.6
95% CI ^b	1.5, 1.8	2.9, 4.0	1.5, 1.9	1.8, 2.5	1.4, 1.7	2.2, 3.0

SRR ≥4-fold increase,° n3/n2 (%)	22/214 (10.3)	84/214 (39.3)	29/212 (13.7)	48/212 (22.6)	19/191 (9.9)	61/191 (31.9)
95% CI ^d	6.6, 15.2	32.7, 46.1	9.4, 19.1	17.2, 28.9	6.1, 15.1	25.4, 39.1

Abbreviations: CI = confidence interval; GMEU = geometric mean ELISA units; GMFR = geometric mean fold rise; GMT = geometric mean titer;

 ID_{50} = inhibitory dilution with a 50% concentration; Max = maximum; Min = minimum; N = number of participants in the assay-specific analysis Set; n1 = number of participants within each visit with non-missing data; n2 = number of participants with non-missing data at both visits of interest; n3 = number of participants who reported \geq 4-fold increase with percentages calculated based on n2 as the denominator; LLOQ = lower limit of quantitation; SRR = seroresponse rate.

^aBaseline was defined as the last non-missing assessment prior to first vaccination. ^bThe 95% CI for GMT and GMFR were calculated based on the tdistribution of the log-transformed values then back transformed to the original scale for presentation. ^cThe SRR was defined as percentage of participants at each post vaccination visit with a titer \geq 4-fold rise in MN₅₀ or ID₅₀ level. ^dThe 95% CI for SRR was calculated using the exact Clopper-Pearson method. ^eThe 95% CI for GMEU and GMFR were calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation. ^fThe SRR was defined as percentage of participants at each post vaccination visit with a titer \geq 4-fold rise in anti-S IgG antibody level.

Note: Values less than LLOQ were replaced by $0.5 \times LLOQ$

medRxiv preprint doi: https://doi.org/10.1101/2023.07.05.23291954; this version posted July 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 4. Overall summary of unsolicited treatment-emergent adverse events through 28 days after

vaccination (Safety Analysis Set^a)

Parameter	NVX-CoV2515	NVX-CoV2373	Bivalent	
rarameter	N = 286	N = 274	N = 269	
Solicited local TEAEs ¹	196 (69.3)	193 (71.0)	173 (64.6)	
Grade 3 or higher	5 (1.8)	1 (0.4)	3 (1.1)	
Solicited systemic TEAEs ²	176 (62.2)	158 (58.1)	166 (61.9)	
Grade 3 or higher	21 (7.4)	10 (3.7)	8 (3.0)	
Any unsolicited TEAE	98 (34.3)	104 (38.0)	91 (33.8)	
Treatment-related	14 (4.9) 8 (2.9)		9 (3.3)	
Severe	0	4 (1.5)	0	
Treatment-related severe	0	0	0	
Any unsolicited serious TEAE	1 (0.3)	1 (0.4)	0	
Treatment-related	0	0	0	
Any unsolicited TEAE leading to vaccination discontinuation	1 (0.3)	1 (0.4)	0	
Treatment-related	1 (0.3)	0	0	
Any unsolicited TEAE leading to study discontinuation	0	1 (0.4)	0	
Treatment-related	0	0	0	
Any unsolicited treatment-emergent MAAE	14 (4.9)	18 (6.6)	13 (4.8)	
Treatment-related	1 (0.3)	0	0	
Treatment-related serious MAAE	0	0	0	
Severe MAAE	0	3 (1.1)	0	
Related Severe MAAE	0	0	0	
Any unsolicited AESI: PIMMC ³	0	1 (0.4)	0	
Treatment-related	0	0	0	
Any unsolicited AESI: complications due to COVID-19	0	0	0	

medRxiv preprint doi: https://doi.org/10.1101/2023.07.05.23291954; this version posted July 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Any myocarditis/pericarditis	0	0	0

Abbreviations: AESI = adverse event of special interest; MAAE = medically attended adverse event; PIMMC =


potentially immune-mediated medical condition; TEAE = treatment-emergent adverse event.


^aParticipants in the safety analysis set are counted according to the treatment received to accommodate for treatment

errors.

Figure 1. Immunogenicity against ancestral and BA.1 variant strains of SARS-CoV-2, following booster vaccination with NVX-CoV2515, NVX CoV2373, or Bivalent NVX-CoV2373 + NVX-CoV2515 (PP1 Analysis Set). (A) Microneutralization titers for the ancestral and BA.1 variant. (B) Anti-rS IgG concentrations for the ancestral and BA.1 variant. Dotted lines represent approximate correlates of protection (CoP) titers reported in phase 3 studies (Fong 2023). (C) Pseudovirus neutralization titers for the ancestral and BA.1 variant. Dotted lines represent approximate CoP titers reported in phase 3 studies (Fong 2023).

Α










Figure 2. Immunogenicity against ancestral and BA.1 variant strains of SARS-CoV-2, following booster vaccination with NVX-CoV2515, NVX CoV2373, or Bivalent NVX-CoV2373 + NVX-CoV2515 (PP2 Analysis Set). (A) Microneutralization titers for the ancestral and BA.1 variant. (B) Anti-rS IgG concentrations for the ancestral and BA.1 variant. Dotted lines represent approximate CoP titers reported in phase 3 studies (Fong 2023). (C) Pseudovirus neutralization titers for the ancestral and BA.1 variant. Dotted lines represent approximate CoP titers reported in phase 3 studies (Fong 2023).

Α





B




Figure 3. Solicited adverse events within 7 days of vaccination (Safety Analysis Set). (A) Frequencies of solicited local treatment-emergent adverse events.

(B) Frequencies of solicited systemic treatment-emergent adverse events.

